Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil had 2,678 Ordinary Shares withheld on June 30, 2026 to cover taxes from vesting restricted stock units. The shares were not sold on the open market but used to satisfy tax obligations.
After this tax-withholding disposition, Patil directly holds 48,871 Ordinary Shares. This type of transaction is routine for equity-based compensation and does not represent a discretionary purchase or sale decision.
Jazz Pharmaceuticals EVP & Chief Financial Officer Philip L. Johnson reported a routine tax-withholding transaction related to equity compensation. On the vesting of previously granted restricted stock units, 3,343 ordinary shares were withheld at $237.72 per share to satisfy tax obligations. After this disposition, he directly holds 56,431 ordinary shares. A footnote also notes he acquired 166 ordinary shares under a Section 423 employee stock purchase plan on May 29, 2026.
Jazz Pharmaceuticals submitted a Section 144 notice listing planned sales of Common Stock by an affiliate and recent dispositions. The filing lists three recent sales by Bruce Cozadd of 6,000 shares on 04/01/2026, 6,000 shares on 05/01/2026, and 6,000 shares on 06/01/2026. The filing also records previously issued stock options dated 02/26/2018 (1,335), 03/05/2018 (4,362), and 02/28/2019 (303).
Jazz Pharmaceuticals plc director Mark Douglas Smith reported an open-market sale of 1,157 ordinary shares at $230.55 per share. After this transaction, he directly holds 9,680 ordinary shares. According to a disclosed Rule 10b5-1 trading plan adopted on March 9, 2026, the sale occurred automatically and was not a discretionary trade.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported an open-market sale of 1,200 ordinary shares on June 10, 2026 at $231.83 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan and occurred automatically. After this transaction, she directly holds 51,549 ordinary shares. A footnote also notes she acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.
JAZZ: A Rule 144 notice lists a broker-facilitated sale and securities effected by the issuer. The filing reports 1,192 shares of Common Stock sold on 05/28/2026 for $282,468.24. It also lists 600 performance shares dated 01/16/2026 and 600 restricted shares dated 03/05/2025.
Jazz Pharmaceuticals plc is asking shareholders to vote at its 2026 annual general meeting on July 23, 2026, in Dublin. Shareholders will elect three directors, ratify KPMG as auditor, approve executive compensation on an advisory basis, and renew key share issuance authorities under Irish law.
The board seeks renewed authority to allot ordinary shares within existing authorized capital and, via a special resolution, to issue shares for cash without pre-emption rights up to 20% of issued share capital for 18 months. A separate proposal would allow adjournment if support for these capital authorities is initially insufficient.
The record date is May 28, 2026, with 62,817,628 ordinary shares entitled to one vote each. The board says 11 of 13 current directors are independent and highlights a classified board, active refreshment, strong committee structure, share ownership guidelines, an annual say‑on‑pay vote, and a Clawback Policy. Non‑employee directors receive cash retainers and annual RSU awards targeted at $400,000.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported a charitable share transfer. On June 3, 2026, she made a bona fide gift of 600 ordinary shares at a stated price of $0.00 per share, reducing her direct holdings to 152,196 shares. A footnote also notes that she acquired 166 ordinary shares through a Section 423 Employee Stock Purchase Plan on May 29, 2026, highlighting ongoing participation in employee equity programs.